Elkem (ELK) Q4 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2025 earnings summary
13 Feb, 2026Executive summary
Entered agreement to sell the majority of the Silicones division to Bluestar, settled via redemption of Bluestar's shares, making minority shareholders the new 100% owners and streamlining the business.
Q4 2025 results were resilient despite weak demand, supported by cost improvements and strong market positions.
Silicones division reclassified as discontinued operations; improved Q4 EBITDA by 6% despite lower sales prices and volumes.
Tragic accident at a French plant resulted in two fatalities; safety remains a top priority and investigations are ongoing.
Board proposed no dividend for 2025 due to share redemption linked to the Silicones sale.
Financial highlights
Q4 2025 operating income was NOK 7,284 million, down 14% year-over-year; EBITDA was NOK 890 million (12% margin), down 24%.
Excluding Silicones, Q4 operating income was NOK 4 billion and EBITDA NOK 485 million (12% margin).
EPS for Q4 2025 was NOK (0.28); full-year EPS NOK (1.05).
Net interest-bearing debt at NOK 11.9 billion; leverage ratio 3.5x LTM EBITDA; equity ratio at 51%.
Cash flow from operations in Q4 2025 was NOK 829 million, driven by lower CapEx and positive working capital changes.
Outlook and guidance
Trade regulations and protective measures expected to continue impacting markets and create uncertainty.
Silicon Products faces subdued demand and is reducing capacity in Norway; negative EBITDA but positive cash flow expected.
Carbon Solutions expects slight improvement in sales volumes, but overall demand remains weak.
Silicones prices in China have increased due to reduced supply, but demand remains weak.
Guidance for 2026 anticipates more than 10% top-line growth and a return to historical earnings levels.
Latest events from Elkem
- All agenda items, including the Bluestar share deal and capital decrease, were approved.ELK
EGM 20269 Mar 2026 - EBITDA stable at NOK 1,030m; net profit up on tax assets, Silicones improved despite weak demand.ELK
Q2 20243 Feb 2026 - EBITDA hit NOK 1,235 million, up 131% year-over-year, driven by Silicones and cost programs.ELK
Q3 202418 Jan 2026 - Strong financial performance and strategic investments drive sustainable growth.ELK
SEB Nordic Seminar presentation14 Jan 2026 - 2024 saw strong financials, strategic portfolio review, and top-tier ESG achievements.ELK
DNB Small & Medium Enterprises Conference presentation14 Jan 2026 - Stable results amid weak markets, with Silicones improving and strategic review ongoing.ELK
Lunch presentation14 Jan 2026 - Divesting Silicones to focus on core growth, backed by strong financials and global leadership.ELK
SEB Nordic Seminar presentation14 Jan 2026 - Q4 EBITDA up 84% YoY; Silicones under review and classified as discontinued operations.ELK
Q4 202423 Dec 2025 - EBITDA up 25% to NOK 898m as Silicones review advances amid market uncertainty.ELK
Q1 202528 Nov 2025